This test is most useful if any of these apply to you.
If your diarrhea has stretched on for weeks, your travel history is recent, or you are living with a weakened immune system, this is one of the first things worth ruling out. Cryptosporidium is a waterborne gut parasite that many routine stool tests miss entirely, which is why it often hides in plain sight.
A stool test for Cryptosporidium species can tell you whether a parasitic infection, not a virus or a food sensitivity, is behind your symptoms. Catching it matters because untreated infection can drag on for months, disrupt nutrient absorption, and in immunocompromised people become chronic and dangerous.
Cryptosporidium species are single-celled parasites (called protozoa) in a family known as Apicomplexa. They infect the cells lining your small intestine and shed tough, egg-like structures (oocysts) into your stool, which can then contaminate water, food, and surfaces. Over 40 species have been named, but two cause most human infections: C. hominis (largely human-to-human) and C. parvum (often picked up from cattle and other livestock).
Because the parasite lives in your gut and sheds into stool, the test looks for three things: intact oocysts (under a microscope), parasite proteins (antigens), or parasite DNA (PCR). A positive result means the parasite is present. This is not a measurement of a hormone or metabolic process. It is a yes-or-no answer about an infection, with some modern tests also estimating how heavy the infection is.
Cryptosporidiosis classically causes watery diarrhea, cramping, nausea, low-grade fever, and fatigue. In otherwise healthy adults it often looks like a bad stomach bug that simply will not quit. Episodes can last one to two weeks, then return. Even after symptoms fade, oocysts can continue shedding in stool for weeks, which matters for transmission and for timing a retest.
In young children and in people with HIV, cancer, or an organ transplant, the picture is different. Infections are more likely to become chronic, more severe, and more likely to cause weight loss, malnutrition, or spread beyond the gut. In one large analysis of HIV-positive people, Cryptosporidium was found in roughly 9 out of every 100 tested, with much higher rates in those with diarrhea and low immune cell counts.
This is not a rare tropical parasite. National surveillance programs in Sweden, Norway, Denmark, and the UK have all found that cryptosporidiosis is common and endemic once labs look for it properly. In one Swedish surveillance study, 12 different Cryptosporidium species and many subtypes were identified in human cases. The catch: most showed up only because the labs used molecular testing, not traditional microscopy.
Realistic risk exposures include drinking from untreated wells, swimming in lakes or pools, contact with calves or lambs (including petting zoos), international travel, daycare settings, and close contact with someone who has diarrhea. Recreational water is a major source of C. hominis outbreaks, while animal and environmental contact tends to drive C. parvum cases.
A positive test confirms active infection, meaning oocysts, antigen, or parasite DNA are present in your stool at the time of sampling. It does not distinguish a first infection from a reinfection, and it does not tell you how you got it. Molecular tests can sometimes identify which species (C. hominis, C. parvum, or a less common species) you have, which can help pinpoint the likely source.
Parasite burden matters clinically. Higher loads tend to track with worse, more watery diarrhea. Lower loads often appear in repeat infections or in asymptomatic carriers, particularly children in endemic regions. Even low-burden or symptom-free infections have been linked to growth faltering and nutritional decline in young children, so a positive test should never be dismissed just because you feel only mildly sick.
In children under five in sub-Saharan Africa and South Asia, Cryptosporidium is one of the leading causes of moderate-to-severe diarrhea. A meta-analysis estimated over 48,000 deaths from the parasite in 2016 and more than 4.7 million disability-adjusted life years lost from acute effects alone. When the parasite's long-term impact on growth was added, the burden rose another 153 percent, to 7.85 million disability-adjusted life years.
Each diarrheal episode was associated with a drop in height-for-age of 0.049 (95% CI minus 0.080 to minus 0.014) and weight-for-age of 0.095 (95% CI minus 0.134 to minus 0.055). The practical meaning: this is not a transient nuisance. In kids, a single infection can stunt growth. In immunocompromised adults, chronic infection can cause dehydration, biliary tract involvement, and in some cases disseminated disease.
A systematic review of adult kidney transplant recipients found significantly elevated rates of Cryptosporidium infection, and the authors recommended screening even asymptomatic transplant patients as part of routine care. Chronic diarrhea in a transplant recipient should trigger Cryptosporidium testing early, not after a broad infectious workup.
In people with HIV, infection rates in one retrospective study reached roughly 9 percent overall, climbing higher among those with diarrhea, low CD4 counts, or those not on antiretroviral therapy. Clinical manifestations also differ by species: C. hominis, C. parvum, and C. meleagridis together account for about 94 percent of typed infections in HIV/AIDS populations.
Unlike a cholesterol or glucose test, there is no numeric reference range here. This is a detection test: the result is positive or negative, sometimes with an estimate of parasite burden from PCR cycle thresholds. Because no standardized clinical cutpoints exist for quantitative levels, the clinical interpretation depends on symptoms, risk factors, and the method your lab used.
| Result | What It Means | What to Do Next |
|---|---|---|
| Negative | No parasite DNA, antigen, or oocysts detected in this stool sample | If symptoms persist, retest with a second sample or a different method. A single negative does not rule out infection. |
| Positive | Active infection present at the time of sampling | Treat, identify the source (water, travel, animal contact, household contact), and consider retesting after treatment to confirm clearance |
| Positive with species ID | Confirmed infection with specific identification (e.g., C. hominis vs C. parvum) | The species can help trace exposure (human-to-human vs animal or environmental) and inform outbreak investigation |
One practical caution: test performance varies significantly by method. Modified Ziehl-Neelsen microscopy has relatively low sensitivity (around 56 percent against PCR in one series). Antigen rapid tests run 43 to 77 percent sensitivity and 88 to 100 percent specificity depending on the kit. PCR and multiplex molecular panels are the most sensitive and specific, often 89 to 100 percent sensitive and 97 to 100 percent specific. Compare your results within the same lab and method over time for the most meaningful trend.
Cryptosporidium does not shed continuously. Oocyst output can fluctuate significantly day to day, which means a single negative stool from a symptomatic person is not reliable. Clinical trials of cryptosporidiosis treatment typically require at least two stool samples collected at least 24 hours apart to confirm a response, precisely because of this variability.
If you have ongoing diarrhea and a negative result from one test, a second sample on a different day, ideally using PCR, is the right next step. This is especially true if your initial test used microscopy or a rapid antigen kit, both of which miss a meaningful fraction of real infections.
Serial testing matters most around treatment. If you test positive and receive a course of nitazoxanide (or another treatment), you should retest with stool samples collected at least 24 hours apart, typically one to two weeks after finishing therapy, to confirm the parasite has cleared. A single post-treatment sample is not enough. In a trial of nitazoxanide in adults, over 90 percent of treated patients had no detectable oocysts in two post-treatment stools, compared with 37 percent on placebo.
For higher-risk groups (immunocompromised, transplant recipients, or households with recurrent exposure), longer follow-up matters. Oocysts can persist for weeks after symptoms fade, and reinfection from the same environmental source is common. If you have a chronically weakened immune system, treat Cryptosporidium testing less like a one-time check and more like any chronic disease marker: baseline, confirm clearance after treatment, then retest if symptoms return.
A positive result means three things should happen in order. First, start treatment. Nitazoxanide is the only FDA-approved therapy for immunocompetent adults and older children, and randomized trials show it shortens diarrhea duration, clears oocysts, and reduces mortality in HIV-negative children. In severely immunocompromised patients, the picture is more complex: nitazoxanide has limited efficacy in advanced HIV, and the priority is restoring immune function (typically through antiretroviral therapy) alongside supportive care.
Second, identify and eliminate the source. Ask: did this come from contaminated water, a pet or livestock, a daycare, a household member? Cryptosporidium oocysts are chlorine-resistant, so municipal water treatment does not always kill them, and pool outbreaks are common. Third, protect others. Oocysts shed in your stool for up to several weeks after symptoms resolve. Meticulous handwashing, avoiding swimming until cleared, and not preparing food for others during active infection are all important.
If your diarrhea has lasted more than two weeks, if you are immunocompromised, if you have lost significant weight, or if standard treatment has not cleared the infection, a gastroenterologist or infectious disease specialist should be involved. This is especially true for transplant recipients and people with advanced HIV, where cryptosporidiosis can become chronic, involve the biliary tract, or require specialized management. Do not wait several months of persistent symptoms before escalating.
Evidence-backed interventions that affect your Cryptosporidium Species level
Cryptosporidium Species is best interpreted alongside these tests.
Cryptosporidium Species is included in these pre-built panels.